These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32739420)

  • 21. Podocyte-specific knockin of PTEN protects kidney from hyperglycemia.
    Wang H; Feng Z; Xie J; Wen F; Jv M; Liang T; Li J; Wang Y; Zuo Y; Li S; Li R; Li Z; Zhang B; Liang X; Liu S; Shi W; Wang W
    Am J Physiol Renal Physiol; 2018 Jun; 314(6):F1096-F1107. PubMed ID: 29361670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Podocyte-specific knockout of cyclooxygenase 2 exacerbates diabetic kidney disease.
    Wang L; Sha Y; Bai J; Eisner W; Sparks MA; Buckley AF; Spurney RF
    Am J Physiol Renal Physiol; 2017 Aug; 313(2):F430-F439. PubMed ID: 28490532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice.
    Steenhard BM; Vanacore R; Friedman D; Zelenchuk A; Stroganova L; Isom K; St John PL; Hudson BG; Abrahamson DR
    PLoS One; 2012; 7(12):e50745. PubMed ID: 23236390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of disease progression on the podocyte cell cycle in Alport Syndrome.
    Frank CN; Hou X; Petrosyan A; Villani V; Zhao R; Hansen JR; Clair G; Salem F; De Filippo RE; Cravedi P; Lemley KV; Perin L
    Kidney Int; 2022 Jan; 101(1):106-118. PubMed ID: 34562503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
    He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
    Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II induces cholesterol accumulation and injury in podocytes.
    Yang Y; Yang Q; Yang J; Ma Y; Ding G
    Sci Rep; 2017 Sep; 7(1):10672. PubMed ID: 28878222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crosstalk Between Lipids and Mitochondria in Diabetic Kidney Disease.
    Ducasa GM; Mitrofanova A; Fornoni A
    Curr Diab Rep; 2019 Nov; 19(12):144. PubMed ID: 31754839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role for transforming growth factor-beta1 in alport renal disease progression.
    Sayers R; Kalluri R; Rodgers KD; Shield CF; Meehan DT; Cosgrove D
    Kidney Int; 1999 Nov; 56(5):1662-73. PubMed ID: 10571774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SOAT1 enhances lung cancer invasiveness by stimulating AKT-mediated mitochondrial fragmentation.
    Mo Y; Lin L; Zhang J; Yu C
    Biochem Cell Biol; 2022 Feb; 100(1):68-74. PubMed ID: 34670102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABCA1 deficiency contributes to podocyte pyroptosis priming via the APE1/IRF1 axis in diabetic kidney disease.
    Ito M; Ducasa GM; Molina JD; Santos JV; Mallela SK; Kim JJ; Ge M; Mitrofanova A; Sloan A; Merscher S; Mimura I; Fornoni A
    Sci Rep; 2023 Jun; 13(1):9616. PubMed ID: 37316538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injury.
    Lim AK; Ma FY; Nikolic-Paterson DJ; Kitching AR; Thomas MC; Tesch GH
    Diabetologia; 2010 Aug; 53(8):1772-82. PubMed ID: 20422398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid biology of the podocyte--new perspectives offer new opportunities.
    Fornoni A; Merscher S; Kopp JB
    Nat Rev Nephrol; 2014 Jul; 10(7):379-88. PubMed ID: 24861084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes.
    Zhang J; Gu C; Lawrence DA; Cheung AK; Huang Y
    Exp Physiol; 2014 May; 99(5):802-15. PubMed ID: 24443353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour necrosis factor-α drives Alport glomerulosclerosis in mice by promoting podocyte apoptosis.
    Ryu M; Mulay SR; Miosge N; Gross O; Anders HJ
    J Pathol; 2012 Jan; 226(1):120-31. PubMed ID: 21953121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SOAT1 deficiency attenuates atherosclerosis by regulating inflammation and cholesterol transportation via HO-1 pathway.
    Wu N; Li RQ; Li L
    Biochem Biophys Res Commun; 2018 Jun; 501(2):343-350. PubMed ID: 29567472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.
    You H; Gao T; Raup-Konsavage WM; Cooper TK; Bronson SK; Reeves WB; Awad AS
    Kidney Int; 2017 Mar; 91(3):671-682. PubMed ID: 27914709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GPR43 deficiency protects against podocyte insulin resistance in diabetic nephropathy through the restoration of AMPKα activity.
    Lu J; Chen PP; Zhang JX; Li XQ; Wang GH; Yuan BY; Huang SJ; Liu XQ; Jiang TT; Wang MY; Liu WT; Ruan XZ; Liu BC; Ma KL
    Theranostics; 2021; 11(10):4728-4742. PubMed ID: 33754024
    [No Abstract]   [Full Text] [Related]  

  • 38. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy.
    Herman-Edelstein M; Scherzer P; Tobar A; Levi M; Gafter U
    J Lipid Res; 2014 Mar; 55(3):561-72. PubMed ID: 24371263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alport syndrome--insights from basic and clinical research.
    Kruegel J; Rubel D; Gross O
    Nat Rev Nephrol; 2013 Mar; 9(3):170-8. PubMed ID: 23165304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice.
    Zhang L; Li R; Shi W; Liang X; Liu S; Ye Z; Yu C; Chen Y; Zhang B; Wang W; Lai Y; Ma J; Li Z; Tan X
    Br J Pharmacol; 2013 Sep; 170(2):426-39. PubMed ID: 23826864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.